From these results, we found that among patients diagnosed with laryngeal cancer, there was a significantly higher percentage of CD19+ B cells (1.42×) and Treg (1.52× for CD3+ CD25+ T cells, 1.29× for CD4+ CD25+ T cells, and 3.39× for CD8+ CD25+ T cells), as well as for CD3+ CD69+ T cells (1.90×), CD4+ CD69+ T cells (2.20×), and CD8+ CD69+ T cells (3.38×), as compared to the control group (Table 2). The gene discussed is CD69; the disease is laryngeal carcinoma.